SCHEMBL4603719

SCHEMBL4603719

CC(C)(C)OC(=O)N1CCC(NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.63
KMT2A Q03164 7/20 0.60
TSHR P16473 2/20 0.57
USP2 O75604 1/20 0.57
HDAC6 Q9UBN7 1/20 0.56
MEN1 O00255 3/20 0.56
EPHX1 P07099 1/20 0.55
MAPT P10636 1/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
KDM4E B2RXH2 1/20 0.53
PKM P14618 1/20 0.53
POLB P06746 1/20 0.53
ALDH1A1 P00352 1/20 0.52
SLC6A12 P48065 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52
MCHR1 Q99705 1/20 0.52
SIGMAR1 Q99720 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8366262 0.89 KMT2A (0.70) HDAC4KMT2AHDAC6MEN1EPHX1
SCHEMBL12426680 0.89 HDAC4 (0.61) HDAC4KMT2ATSHRHDAC6MEN1
SCHEMBL25401822 0.88 HDAC4 (0.60) HDAC4KMT2ATSHRHDAC6MEN1
SCHEMBL7532504 0.88 HDAC4 (0.60) HDAC4KMT2AHDAC6MEN1EPHX1
SCHEMBL17572994 0.88 HDAC4 (0.60) HDAC4KMT2ATSHRHDAC6MEN1
SCHEMBL13199301 0.87 KDM4E (0.68) HDAC4KMT2AMEN1EPHX1KDM4E
SCHEMBL1424917 0.87 KMT2A (0.66) KMT2ATSHRUSP2MEN1MAPT
SCHEMBL28457523 0.86 ALDH1A1 (0.70) HDAC4KMT2AMEN1EPHX1MAPT
SCHEMBL27633457 0.86 KMT2A (0.61) HDAC4KMT2AMEN1ALDH1A1
SCHEMBL28975873 0.85 HDAC4 (0.60) HDAC4KMT2AHDAC6MEN1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008141057-A1 DEUTERATED PIMAVANSERIN 1- (4-FLU0R0BENZYL) -3- (4-ISOBUTOXYBENZYL) -1- ( L-METHYL-PIPERIDIN-4-YL) -UREA AUSPEX PHARMACEUTICALS, INC. (US) 2008-11-20 WO disclosed
WO-2008141057-A1 DEUTERATED PIMAVANSERIN 1- (4-FLU0R0BENZYL) -3- (4-ISOBUTOXYBENZYL) -1- ( L-METHYL-PIPERIDIN-4-YL) -UREA AUSPEX PHARMACEUTICALS, INC. (US) 2008-11-20 WO disclosed
US-20080280886-A1 SUBSTITUTED UREAS AUSPEX PHARMACEUTICALS, INC. (US) 2008-11-13 US disclosed
US-20080280886-A1 SUBSTITUTED UREAS AUSPEX PHARMACEUTICALS, INC. (US) 2008-11-13 US disclosed
US-20080280886-A1 SUBSTITUTED UREAS AUSPEX PHARMACEUTICALS, INC. (US) 2008-11-13 US disclosed
US-20080234333-A1 Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof KANG JAE-HOON 2008-09-25 US disclosed
EP-1915342-A1 A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2008-04-30 EP disclosed
WO-2006115353-A1 A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234333-A1 Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof PDF, PEPD, DHPS HDAC4 267/4885KMT2A 1445/4885TSHR 3586/4885
US-20080280886-A1 SUBSTITUTED UREAS HTR4, HTR5A, HTR6 HDAC4 1268/4885KMT2A 2286/4885TSHR 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.